Medicare-backed breast cancer screenings skyrocket, but do patients benefit?

July 1, 2014, Yale University

Breast cancer screening costs for Medicare patients skyrocketed between 2001 and 2009, but the increase did not lead to earlier detection of new breast cancer cases, according to a study published by Yale School of Medicine researchers in the July 1 Journal of the National Cancer Institute.

While the number of performed among Medicare patients remained stable during the same time period, the study focused on the adoption of newer imaging technologies in the Medicare population, such as . Brigid Killelea, M.D., assistant professor of surgery, and Cary Gross, M.D., professor of internal medicine at Yale School of Medicine and director of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale Cancer Center, were lead authors of the study.

"Screening mammography is an important tool, but this rate of increase in cost is not sustainable," said Killelea, assistant professor of surgery. "We need to establish for older women that utilize technology appropriately, and minimize unnecessary biopsies and over-diagnosis to keep costs under control."

Gross, Killelea, and other members of the Yale COPPER research team explored trends in the cost of . They identified the use of newer, more expensive approaches including digital mammography and computer aided detection (CAD), as well as the use of other treatment tools and subsequent procedures such as breast MRI and biopsy, between 2001-2002 and 2008-2009. They also assessed the change in breast cancer stage and incidence rates between the two time periods.

They found that use of was similar between the time periods —at around 42% of female Medicare beneficiaries without a history of breast cancer. There was a large increase in the use of digital mammography technology, which is more expensive than standard film technology ($115 vs. $73 per mammogram) and has not been shown in clinical trials to be superior for women 65 years or older.

The team also found a considerable increase in the use of other newer, more expensive screening and related-adjunct technologies. As a result, Medicare spending for breast screening and related procedures increased from $666 million (in 2001-2002) to $962 million (2008-2009).

While the United States Preventive Services Task Force does not recommend breast cancer screening for women age 75 years and older, the COPPER team found that Medicare still spent an increasing amount per woman 75 years and older in the study.

"We need further studies to identify which women will benefit from screening, and how to screen effectively and efficiently," said Gross. "But we cannot simply adopt new technologies because they theoretically are superior—the health system cannot sustain it, and more importantly our patients deserve a sustained effort to determine which approaches to screening are effective and which ones are not. In some instances, breast cancer screening can save lives. But no woman wants to undergo testing if it is likely to cause more harm than good.

Explore further: Costly breast cancer screenings don't add up to better outcomes

More information: Journal of The National Cancer Institute (July 1, 2014). www.oxfordjournals.org/licensi … =10.1093/jnci/dju159

Related Stories

Costly breast cancer screenings don't add up to better outcomes

January 7, 2013
Even though Medicare spends over $1 billion per year on breast cancer screenings such as a mammography, there is no evidence that higher spending benefits older women, researchers at Yale School of Medicine found in a study ...

Screening has prevented half a million colorectal cancers

June 3, 2014
An estimated half a million cancers were prevented by colorectal cancer screening in the United States from 1976 to 2009, report researchers from the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center ...

3-D mammography detects more invasive cancers and reduces call-back rates

June 24, 2014
Reporting in the June 25 issue of JAMA, researchers from Penn Medicine and other institutions found that 3D mammography—known as digital breast tomosynthesis— found significantly more invasive, or potentially lethal, ...

New study suggests benefit of screening on breast cancer deaths

June 17, 2014
Invitation to modern mammography screening may reduce deaths from breast cancer by about 28 percent, suggests a study from Norway published in BMJ. This means that for every 10,000 women invited to screening, about 27 deaths ...

Nonscreened patients with breast cancer need more treatment than screened patients

May 7, 2014
Screening 40- to 49-year-old women for breast cancer has additional benefits beyond the proven decrease in mortality rate. Patients screened with mammography are statistically less likely to undergo chemotherapy, avoiding ...

3-D breast imaging could revolutionize cancer screening

June 17, 2014
In community-based radiology practice, mammography screening with 3D digital breast tomosynthesis (DBT) yielded lower recall rates, an increased overall cancer detection rate, and an increased detection rate for invasive ...

Recommended for you

Metastatic cancer gorges on fructose in the liver

April 26, 2018
Biomedical engineers at Duke University have demonstrated that metastatic cancer cells can reprogram their metabolism to thrive in new organs. Specifically, the research shows that cells originating from colorectal cancer ...

Breast cancer genes a real risk for men, too

April 26, 2018
(HealthDay)—Few American men are screened for gene mutations that can greatly increase their risk of breast and other types of cancers, a new study reveals.

Largest-ever study of thyroid cancer genetics finds new mutations, suggests immunotherapy

April 26, 2018
University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid ...

Molecular culprit behind virus-mediated chronic inflammation and cancers identified

April 26, 2018
Within cells infected by Kaposi sarcoma herpesvirus (KSHV), the human protein CADM1 interacts with viral proteins to promote chronic inflammation, which plays a major role in the development of cancers caused by KSHV. Richard ...

PARP-1 may be key to effectiveness of PARP inhibitors, and now researchers can image it

April 26, 2018
Penn Medicine researchers have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer—and they've also proven they have a ...

Blood cancer precursor found in 9/11 firefighters

April 26, 2018
A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.